NOE 109
Alternative Names: Decoglurant - Noema Pharma; NOE-109Latest Information Update: 28 Jan 2024
At a glance
- Originator Roche
- Developer Noema Pharma
- Class Small molecules
- Mechanism of Action Metabotropic glutamate receptor 2 antagonists; Metabotropic glutamate receptor 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Neurological-disorders in Switzerland (Parenteral)
- 08 Sep 2021 Noema Pharma plans a phase II trial for Neurological disorders (Noema Pharma pipeline, September 2021)
- 01 Dec 2020 NOE 109 licensed to Noema Pharma worldwide